No record found
No record found
No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.
| Kashif Hussain Siddiquie | CEO |
| Atif Hussain Siddiqi | Chairman |
| Muhammad Saeed | Company Secretary |
F.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi
M/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants
June
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Mar 9, 2026 | Condensed Interim Financial Statements for the Half Year ended December 31, 2025 (with shariah compliant disclosure) | View PDF |
| Feb 27, 2026 | Condensed Interim Financial Statements for the Half Year ended December 31, 2025. | View PDF |
| Feb 27, 2026 | Financial Results for the half year ended December 31, 2025 | View PDF |
| Jan 2, 2026 | Financial results for the quarter ended September 30, 2025. | View PDF |
| Nov 6, 2025 | Financial Results Summary for Year ended 2025 | View PDF |
| Date | Title | Document |
|---|---|---|
| Feb 19, 2026 | Board Meeting for Accounts for the Period Ended 31st December 2025 | View PDF |
| Jan 1, 2026 | Extracts of resolution passed in the board of directors meeting of Liven Pharma Limited - December 30, 2025 | View PDF |
| Dec 26, 2025 | Board meeting for the consideration of Quarterly accounts for the period ended September 30, 2025 | View |
| Dec 22, 2025 | Board Meeting other than financial results | View PDF |
| Dec 8, 2025 | Certified True Copy of Passed/Adopted in the 34th Annual General Meeting of Liven Pharma Limited | View PDF |
| Date | Title | Document |
|---|---|---|
| Feb 18, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Feb 18, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Feb 18, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Feb 18, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Feb 18, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Financials
All numbers in thousands (000's) except EPS
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 127,272 | 245,093 | ||
| Profit after Taxation | (584,460) | 41,744 | (12,327) | (14,291) |
| EPS | (8.37) | 1.04 | (1.02) | (1.18) |
| Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | |
|---|---|---|---|---|
| Sales | 54,559 | 8,821 | 14,755 | 17,126 |
| Profit after Taxation | 28,210 | (30,157) | (9,609) | (9,491) |
| EPS | (0.30) | (0.32) | (0.10) | (0.10) |

Ratios
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 14.11 | 25.46 | ||
| Net Profit Margin (%) | (459.22) | 17.03 | ||
| EPS Growth (%) | (901.72) | 202.35 | 13.56 | 2.48 |
| PEG | 0.01 | 0.04 | (1.06) | (4.29) |










Feedback
Terms of Use
https://www.psx.com.pk